ATE362990T1 - Virusähnliche partikel, vorbereitung und verwendung in screening und funktionelle genomanwendung - Google Patents

Virusähnliche partikel, vorbereitung und verwendung in screening und funktionelle genomanwendung

Info

Publication number
ATE362990T1
ATE362990T1 AT00949236T AT00949236T ATE362990T1 AT E362990 T1 ATE362990 T1 AT E362990T1 AT 00949236 T AT00949236 T AT 00949236T AT 00949236 T AT00949236 T AT 00949236T AT E362990 T1 ATE362990 T1 AT E362990T1
Authority
AT
Austria
Prior art keywords
particles
virus
preparation
screening
functional genome
Prior art date
Application number
AT00949236T
Other languages
English (en)
Inventor
Nicholas Hunt
Original Assignee
Evotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Ag filed Critical Evotec Ag
Application granted granted Critical
Publication of ATE362990T1 publication Critical patent/ATE362990T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4722—G-proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/586—Liposomes, microcapsules or cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Communicable Diseases (AREA)
AT00949236T 1999-06-30 2000-06-30 Virusähnliche partikel, vorbereitung und verwendung in screening und funktionelle genomanwendung ATE362990T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14126899P 1999-06-30 1999-06-30
EP99112451 1999-06-30
EP00106109 2000-03-21
EP00110363 2000-05-15

Publications (1)

Publication Number Publication Date
ATE362990T1 true ATE362990T1 (de) 2007-06-15

Family

ID=56290037

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00949236T ATE362990T1 (de) 1999-06-30 2000-06-30 Virusähnliche partikel, vorbereitung und verwendung in screening und funktionelle genomanwendung

Country Status (7)

Country Link
EP (1) EP1187928B1 (de)
JP (1) JP2003504014A (de)
AT (1) ATE362990T1 (de)
AU (1) AU6267000A (de)
DE (1) DE60034947T2 (de)
DK (1) DK1187928T3 (de)
WO (1) WO2001002551A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763258B2 (en) 1997-05-20 2010-07-27 The Trustees Of The University Of Pennsylvania Virus-like particles (VLPs) comprising heterologous multiple membrane spanning proteins
US20040014033A1 (en) 1999-06-30 2004-01-22 Evotec Biosystems Ag, A Corporation Of Germany Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US7476517B2 (en) 1999-06-30 2009-01-13 Evotec Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US7592008B2 (en) 2000-11-20 2009-09-22 The Board Of Trustees Of The University Of Illinois, A Body Corporate And Politic Of The State Of Illinois Membrane scaffold proteins
US7083958B2 (en) 2000-11-20 2006-08-01 The Board Of Trustees Of The University Of Illinois Membrane scaffold proteins
US7622437B2 (en) 2000-11-20 2009-11-24 The Board Of Trustees Of The University Of Illinois Tissue factor compositions and methods
WO2002040501A2 (en) 2000-11-20 2002-05-23 The Board Of Trustees Of The University Of Illinois Membrane scaffold proteins
DE60037263T2 (de) * 2000-12-29 2008-10-09 Evotec Ag Virus-ähnliche Partikel, ihre Herstellung und ihre Verwendung beim pharmazeutischen Screening und funktionelle Genomanwendungen
US7070978B2 (en) 2001-06-20 2006-07-04 Toudai Tlo, Ltd. Method for expressing and purifying proteins using budded baculovirus
EP1632778A3 (de) 2001-07-09 2006-03-29 Euroscreen S.A. Natürlicher Ligand von gpcr chemr23 und dessen Verwendungen
JP2003052370A (ja) * 2001-08-16 2003-02-25 Sentan Kagaku Gijutsu Incubation Center:Kk 発芽バキュロウィルスを用いた機能を有する膜型受容体蛋白質の発現法
AU2002359332A1 (en) * 2001-10-30 2003-05-12 Vertex Pharmaceuticals Incorporated Noe-nmr based methods for the identifycation of compounds which can bind to membrane receptors
JP2003177131A (ja) * 2001-12-11 2003-06-27 Olympus Optical Co Ltd 生物学的な結合親和性を検出する方法
AU2003202542A1 (en) 2002-01-07 2003-07-24 Euroscreen S.A. Ligand for g-protein coupled receptor gpr43 and uses thereof
WO2004003143A2 (en) * 2002-06-26 2004-01-08 Advanced Bionutrition Corporation Viruses and virus-like particles for multiple antigen and target display
JP2004093527A (ja) * 2002-09-04 2004-03-25 Center For Advanced Science & Technology Incubation Ltd 蛍光共鳴エネルギー転移を用いた蛋白質の分析方法
US8574590B2 (en) * 2003-07-30 2013-11-05 Integral Molecular, Inc. Lipoparticles comprising proteins, methods of making, and using the same
EP1773303A2 (de) * 2004-05-25 2007-04-18 Chimeracore, Inc. Selbstmontierendes nanopartikel-wirkstofffreisetzungssystem
US8377691B2 (en) * 2006-01-26 2013-02-19 Integral Molecular, Inc. Lipoparticles comprising ion channels, methods of making and using the same
ATE460922T1 (de) 2006-04-07 2010-04-15 Chimeros Inc Zusammensetzungen und verfahren zur behandlung von b-zellen-malignomen
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
WO2013034666A2 (en) 2011-09-08 2013-03-14 Chemcom S.A. Novel pheromonal receptor of spodoptera littoralis (lepidoptera, noctuidae) and identification of natural ligand of said receptor and uses thereof
JP2014527072A (ja) 2011-09-09 2014-10-09 バイオメド リアルティー， エル．ピー． ウイルスタンパク質の集合を制御するための方法および組成物
WO2013174999A1 (en) * 2012-05-24 2013-11-28 Vib Vzw Virus-like particle based protein-protein interaction
PL3004157T3 (pl) 2013-05-31 2018-03-30 Chemcom S.A. Receptory węchowe zaangażowane w odbieranie kwasów karboksylowych z potu oraz ich zastosowanie
EP3242685B1 (de) 2015-01-09 2022-05-04 AdAlta Limited Cxcr4-bindende moleküle
GB201504859D0 (en) 2015-03-23 2015-05-06 Vib Vzw Viral particle based small molecule-protein interaction trap
EP4059516A1 (de) * 2016-04-22 2022-09-21 Vaccinex, Inc. Integrale membranproteinanzeige auf extrazellulären umhüllten virionen des pockenvirus
JP7263355B2 (ja) 2017-12-05 2023-04-24 ケムコム エス アー ムスクの香りの知覚に関与する嗅覚受容体およびその使用
US11261216B2 (en) * 2018-12-28 2022-03-01 The Board Of Trustees Of The Leland Stanford Junior University Engineered hepatitis B core polypeptide
CN120390648A (zh) * 2022-12-14 2025-07-29 小马尔特·乌斯塔夫 用于靶向捕获膜蛋白的工程化的病毒样颗粒

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330661B1 (de) * 1986-11-01 1994-01-12 British Bio-Technology Limited Fusionsproteine und -partikel
EP0768377A1 (de) * 1988-09-02 1997-04-16 Protein Engineering Corporation Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
AU4773293A (en) * 1992-07-16 1994-02-14 Oxford University Multiple particulate antigen delivery system
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
GB9304239D0 (en) * 1993-03-01 1993-04-21 British Bio Technology Viral particles
WO1996030523A2 (en) * 1995-03-31 1996-10-03 Hans Wolf Antigen presentation system based on retrovirus-like particles
AU5703796A (en) * 1995-05-10 1996-11-29 Introgene B.V. Improved retroviral vectors, especially suitable for gene th erapy
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
US8349602B1 (en) * 1996-04-19 2013-01-08 Xenogen Corporation Biodetectors targeted to specific ligands
JP2000515741A (ja) * 1996-07-17 2000-11-28 アメリカ合衆国 感染性パピローマウイルス偽ウイルス粒子
AUPO434196A0 (en) * 1996-12-24 1997-01-23 Crown In The Right Of The Queensland Department Of Health, The An improved therapeutic
WO1998049195A1 (en) * 1997-04-29 1998-11-05 Universiteit Utrecht Corona virus-like particles as tools for vaccination and therapy
US6451527B1 (en) * 1997-08-29 2002-09-17 Selective Genetics, Inc. Methods using genetic package display for selecting internalizing ligands for gene delivery
US6171591B1 (en) * 1997-12-08 2001-01-09 Pentamer Pharmaceuticals, Inc. Recombinant nodavirus compositions and methods
DE69935313T2 (de) * 1998-01-09 2007-11-15 Phylogica Ltd., Northbridge Nachweisverfahren für peptide
GB9806666D0 (en) * 1998-03-27 1998-05-27 Stanley Margaret Antigen preparation and use
EP0959135A1 (de) * 1998-05-20 1999-11-24 Introgene B.V. Protein-Display und zielgerichtete Darreichung zum Zellreceptor
EP0960942A3 (de) * 1998-05-20 2000-01-12 Introgene B.V. Zielgerichtete Abgage durch einen Aminosäuretransporter
CA2339324C (en) * 1998-08-14 2011-05-31 Robert S. Lowe Protein delivery system using human papillomavirus virus-like particles

Also Published As

Publication number Publication date
DE60034947D1 (de) 2007-07-05
WO2001002551A2 (en) 2001-01-11
WO2001002551A3 (en) 2001-11-08
DE60034947T2 (de) 2008-01-24
JP2003504014A (ja) 2003-02-04
EP1187928A2 (de) 2002-03-20
DK1187928T3 (da) 2007-10-08
AU6267000A (en) 2001-01-22
EP1187928B1 (de) 2007-05-23

Similar Documents

Publication Publication Date Title
DE60034947D1 (de) Virusähnliche partikel, vorbereitung und verwendung in screening und funktionelle genomanwendung
SI1685243T1 (sl) Imortalizirane ptičje celične linije za produkcijo virusov
BR0011499A (pt) Moléculas de ácido nucléico oriundas de plantas e células de,planta transgênicas de trigo e o seu uso para a produção de amido modificado
DE50014020D1 (de) Reinstlufteinrichtung für den Pharmazie-, Lebensmittel- und biotechnischen Bereich
ATE483970T1 (de) Zellen zur entdeckung von medikamenten
HRP20030948B1 (hr) Taci-imunoglobulin fuzijski proteini
TR200200763T2 (tr) Antiviral bileşimler
DE60142614D1 (de) Inität
WO2003076592A3 (en) Novel method for delivery and intracellular synthesis of sirna molecules
EP1597350A4 (de) Zur behandlung und zum nachweis einer influenzavirusinfektion geeignete nukleinsäuremoleküle, polypeptide, antikörper und diese enthaltende zusammensetzungen
DE69942055D1 (de) Durch Sprengung mit Wasserdampf von Holzausgangsmaterialien erzeugte Bruchstücke, solche Bruchstücke als Aggregat aufweisendes Holzmaterial, ihre Herstellungsverfahren und Maschinen
ATE326985T1 (de) Lyophilisierte pharmazeutische zusammensetzung von propofol
MA27410A1 (fr) Nouveaux composes pyridopyrimidinone leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2006116181A3 (en) Regulatory t cell mediator proteins and uses thereof
DK1051158T3 (da) Farmaceutiske præparater i form af polymere mikropartikler fremstillet ved ekstrudering og sfæronisering
CY1107431T1 (el) Σωματιδια για γoνιδιακη θεραπεια
NO20020367D0 (no) Konjugater og fremgangsmåter for fremstilling derav, og deres anvendelse for transportering av molekyler via biologiskemembraner
DK1082423T3 (da) Cyclin E2-gener og -proteiner
WO2005042566A3 (en) Antiangiogenicpeptides for treating or preventing endometriosis
DE59811437D1 (de) Oxiranyl-triazolinthione und ihre verwendung als mikrobizide
DE60037263D1 (de) Virus-ähnliche Partikel, ihre Herstellung und ihre Verwendung beim pharmazeutischen Screening und funktionelle Genomanwendungen
DE60003324D1 (de) Grosse russpartikel zur verminderung der benötigten energie zum mischen von sehr harten, steifen reifenzusammensetzungen
WO1999063941A3 (en) Novel hepatitis c virus peptides and uses thereof
DE69728447D1 (de) Veränderte, kleine rna-viren
DE60334097D1 (de) Methode zur herstellung von viralen partikeln welche eine veränderte zellbindungsaktivität haben und deren verwendungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties